

NOTIFICATION TO SHAREHOLDERS OF TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES OR PERSON CLOSELY ASSOCIATED WITH THEM

DATE: February 6, 2017

London (United Kingdom) - Stallergenes Greer plc (the “Company”) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, has today sent a notice to shareholders, the full table of which is set out below.

1.	Details of PDMR / person closely associated with them (‘PCA’)	
a)	Name	Elmar Schnee
b)	Position / status	Director
c)	Initial notification / amendment	Initial Notification
2.	Details of the issuer	
a)	Name	Stallergenes Greer plc
b)	LEI	GB00BZ21RF93 - DD019299
2.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument	Ordinary shares of €1 each in the capital of Stallergenes Greer plc ISIN GB00BZ21RF93
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s)
		Volume(s)
		€27.03
		1,000
d)	Aggregated information Aggregated volume Price	1,000 € 27.03
e)	Date of the transaction	2016-09-06
f)	Place of the transaction	Euronext Paris

ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>

This document (including information incorporated by reference in this document), oral statements made and other information published by the Company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe," "expects," "project," "estimated," "forecast," "should," "plan," "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in the Company's 2015 annual report published on 29 April 2016 on the Company's website www.stallergenesgreer.com. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

Contacts:

Investor and Analyst Relations

Peter Bühler
 Chief Financial Officer
 Tel: +33 1 55 59 23 22
 Email: investorrelations@aresallergyco.com

Media Relations Agency

Havas Worldwide Paris
 Jean-Baptiste Froville
 Tel: +33 1 58 47 95 39
 Email: jean-baptiste.froville@havasww.com

Investor Relations Agency

FTI Consulting
 Arnaud de Cheffontaines
 Tel: +33 1 47 03 69 48
 Email: arnaud.decheffontaines@fticonsulting.com